Feuerstein's Biotech-Stock Mailbag

Welcome back and thanks for reading the last Biotech Mailbag for 2007. I'm going to put this column on a two-week hiatus after today and return rejuvenated in January.

Before we get to this week's emails, I want to express sincere gratitude to everyone who took time to send me comments and questions, praise and pans, over the past 12 months.

We covered a lot of ground this year, and I know I took a closer look at some biotech stocks that would have skipped right past me if your emails hadn't brought them to my attention. I learned a lot, and I hope you did too. (If you made some money as well, all the better.)

Some of my Mailbag musings generated controversy, even anger. There were some sharp disagreements over Dendreon(DNDN Quote). I got heat on Encysive Pharmaceuticals(ENCY Quote), Medarex(MEDX Quote) and Introgen Therapeutics(INGN Quote), and more recently Delcath Systems(DCTH Quote). That's all good.

If you spent any time with the Mailbag this year, you know I'm usually not flinty with opinion. But at the same time, I hope I convey to you fairness and accountability. (And fun, we have to have fun at the Mailbag!) The Mailbag has no agenda; it's just an honest attempt to assess biotech stocks based on the facts. And when I get something wrong -- and that does and will happen -- I'll always admit my error and try to learn something from it.